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Abstract 
 
Background: Advancing age is associated with a greater prevalence of coronary artery 
disease in heart failure (HF) with reduced ejection fraction and with a higher risk of 
complications following coronary artery bypass grafting (CABG). Whether the efficacy of 
CABG compared with medical therapy (MED) in patients with HF due to ischemic 
cardiomyopathy is the same in patients of different age is unknown.  
Methods: 1212 patients (median follow up 9.8 years) with ejection fraction ≤35% and 
coronary disease amenable to CABG were randomized to CABG or MED in the STICH trial. 
Results:  Mean age at trial entry was 60 years; 12% women; 36% non-white; baseline EF 
28%. For the present analyses, patients were categorized by age quartiles: Q1 ≤54 years, Q2 
>54 and ≤60 years, Q3 >60 and ≤67 years, Q4 >67 years. Older vs. younger patients had 
more comorbidities. All-cause mortality was higher in older compared with younger patients 
assigned to MED (79 vs. 60% for Q4 and Q1, respectively; log-rank p=0.005) and CABG (68 
vs. 48% for Q4 and Q1, respectively; log-rank p<0.001). In contrast, CV mortality was not 
statistically significantly different across the spectrum of age in the MED group (53 vs. 49% 
for Q4 and Q1, respectively; log-rank p=0.388) or CABG group (39 vs 35% for Q4 and Q1, 
respectively;   log-rank p=0.103). CV deaths accounted for a greater proportion of deaths in 
the youngest vs oldest quartile (79% vs 62%). The effect of CABG vs MED on all-cause 
mortality tended to diminish with increasing age (pinteraction=0.062), while the benefit of 
CABG on CV mortality was consistent over all ages (pinteraction =0.307). There was a greater 
reduction in all-cause mortality or CV hospitalization with CABG versus MED in younger 
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compared with older patients (pinteraction = 0.004).  In the CABG group, cardiopulmonary 
bypass time or days in intensive care did not differ for older vs. younger patients. 
Conclusions:  CABG added to MED has a more substantial benefit on all-cause mortality and 
all-cause mortality and CV hospitalization in younger compared to older patients.  CABG 
added to MED has a consistent beneficial effect on CV mortality regardless of age.  
Clinical Trial Registration:  ClinicalTrials.gov Identifier:  NCT00023595 
Keywords: heart failure, ischemic cardiomyopathy, coronary artery bypass grafting, age 
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Clinical Perspective 
What is new?  
The 10 year follow-up of the STICH trial demonstrated a reduction in all-cause mortality in 
patients with heart failure who received CABG added to guideline-directed medical therapy 
compared with medical therapy alone.  In the present analyses, we report that the 
reduction in all-cause mortality with CABG was most pronounced in younger patients.  The 
impact of CABG on all-cause mortality and the combination of all-cause mortality and CV 
hospitalization is diminished in older patients. The benefit of CABG on CV mortality is 
consistent across all ages in the trial.   
What are the clinical implications?  
Patients presenting with heart failure who are potential candidates for CABG should be 
investigated to establish if they have coronary heart disease amenable to surgical 
revascularization.  Cardiologists and cardiac surgeons can offer appropriate patients CABG, 
in addition to optimal medical therapy, with the knowledge that CV mortality is reduced 
across all age groups included in the trial.  When considering older patients for surgical 
revascularization, clinicians should be aware that the reductions in all-cause mortality and 
all-cause mortality and CV hospitalization seen in younger patients are diminished with 
increasing age.           
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Introduction 
Older patients with heart failure (HF) more commonly have coronary artery disease (CAD) as 
the cause of their HF than younger patients.1 With improving survival, the prevalence of 
patients living with both ischemic heart disease and HF who potentially require coronary 
revascularization has risen.2 Management of these patients is difficult; many have angina, 
evidence of ischemia or myocardial viability and are considered for coronary 
revascularization. As there have been no randomized trials of coronary percutaneous 
intervention in populations with HF, the benefits or harms of this approach are unknown.  
However, results from the Surgical Treatment for Ischemic Heart Failure (STICH) trial 
(including the extended follow up study)3,4 demonstrated improved clinical outcomes 
following Coronary Artery Bypass Grafting (CABG); over a median of 9.8 years, the risk of all-
cause death, death from cardiovascular causes, and all cause death or hospitalization from 
cardiovascular causes was significantly lower in those randomized to receive CABG and 
guideline-directed medical therapy compared with medical therapy alone.4  
Increasing age is associated with worse short and long-term outcomes following 
CABG in general populations of patients with CAD.5,6  As increasing age is associated with 
higher mortality in patients with HF 7, clinicians may be reluctant to recommend older 
patients for revascularization with CABG due to uncertainty of its benefits. We examined 
the effect of CABG and guideline-directed medical therapy compared with guideline-
directed medical therapy alone according to age in the STICH trial. 
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Methods 
The STICH trial 3 (ClinicalTrials.gov number, NCT00023595) and extended follow-up 4 have 
been described in detail previously. The median follow-up time was 9.8 years (interquartile 
range, 9.1 to 11.0 years). Patients ≥18 years old with CAD that was amenable to treatment 
with CABG and an ejection fraction of 35% or less, as determined at each enrolling site 
(measured by CMR ventriculogram, gated SPECT ventriculogram, echocardiography or 
contrast ventriculogram within 3 months of trial entry) were enrolled. Patients were 
randomized to CABG with guideline-directed medical therapy versus medical therapy alone.  
Trial sites were prompted by the STICH team to implement guideline recommended optimal 
medical therapy in both randomized arms. Patients were eligible for randomization only if 
they did not have a coronary stenosis of ≥50% of the diameter of the left main coronary 
artery and if they did not have Canadian Cardiovascular Society class III or IV angina while 
receiving medical therapy.  The extended follow-up study was a pre-specified extension of 
the STICH trial with follow-up extended an additional 5 years. The study complied with the 
Declaration of Helsinki, and the locally appointed ethics committee approved the research 
protocol. Informed consent was obtained from the subjects or their legally authorized 
representative. 
 
Outcomes 
The primary outcome was all cause death and the 2 key secondary outcomes were 
cardiovascular (CV) death and a composite of all-cause death or CV hospitalizations.  All 
deaths were classified by a blinded clinical events committee according to pre-specified 
criteria. 
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Statistical Analysis 
The randomized population was divided according to age into quartiles: Q1  
≤54 years, Q2 >54 and ≤60 years, Q3 >60 and ≤67 years, Q4 >67 years. Baseline 
characteristics are presented by quartile of age. Continuous variables are presented as 
medians with 25th and 75th percentiles and categorical variables as counts with percentages. 
The distribution of continuous variables was tested using the Jonckheere-Terpstra trend test 
(Spearman correlation p values are presented in the Supplemental Materials) and 
categorical variables using the Cochran-Armitage trend test. Kaplan-Meier rates were 
computed for each age group by randomized treatment.8 The relationship between age as a 
continuous variable and outcomes was examined and graphed using the mfpi command in 
Stata as a fractional polynomial.9,10  The effect of randomized therapy (CABG with guideline-
directed medical therapy versus medical therapy alone) by age was examined in a Cox 
proportional hazards model with an interaction term of randomized therapy and age as a 
continuous variable. All models were unadjusted and analyses conducted using SAS version 
9.4 (SAS Institute Inc., Cary, NC, USA) and Stata version 14 (College Station, TX, USA) with 
p<0.05 considered statistically significant. 
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Results 
Baseline characteristics by age     
The 1212 patients were split into 4 quartiles. Patients in the oldest quartile (age >67 years) 
tended to be more often women and of white race (Table 1 and Supplemental Material).  
Older patients had a higher prevalence of comorbidities, except for hyperlipidemia and 
depression. The proportion of patients with no or CCS class I angina was highest in the 
oldest age group. Older patients had a shorter 6-minute walk test distance. Systolic blood 
pressure was higher and heart rate was lower in the older group. Hemoglobin was lower 
and kidney function was worse in the older age groups.  Within the oldest quartile, 75 (6%) 
were over the age of 75 years and 15 (1%) over the age of 80 years (Supplemental Material) 
 
Baseline medical and device therapy were similar across ages (Table 2) except for greater 
use of warfarin (due to more atrial fibrillation) and loop or thiazide diuretics in older 
patients. The proportion on guideline directed medical therapy fell in the older compared to 
younger patients over time (Supplemental Material). In each age quartile there was no 
difference in medical therapies in the CABG compared to medical therapy group 
(Supplemental Material). 
 
Echocardiographic measures and coronary anatomy according to age 
Left ventricular ejection fraction was similar over the age range, although end diastolic 
volume indexed to body surface area was lower in the oldest age group (Table 3). The E 
wave velocity and E/A ratio were lower in the older group than younger groups but there 
were no significant differences in the E/e’ ratio. The presence and severity of mitral 
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regurgitation did not vary significantly.  Older patients had more vessels with a coronary 
stenosis but less proximal left anterior descending artery stenosis. The Duke coronary artery 
disease severity index increased with age.  
 
Procedural details and complications of CABG by age 
In the CABG group, there was no difference in the number of conduits used by age but the 
older group was more likely to have more distal anastomoses performed (Table 4).  There 
was no difference in time on bypass or length of stay in the intensive care unit by age. The 
proportion who had to return to the operating room, developed mediastinitis or intubation 
for pulmonary edema or who experienced a cardiac arrest was not different by age. New 
onset atrial fibrillation rose with increasing age as did the need for inotropes for low cardiac 
output.  
 
Effect of age on 10 Year outcomes 
All-cause mortality increased with increasing age in both MED (60 vs. 79% for Q1 and Q4, 
respectively; log-rank p=0.005) and CABG (48 vs. 68% for Q1 and Q4, respectively; log-rank 
p<0.001) groups.  CV mortality was higher in the older quartiles compared to the younger 
quartiles, but this difference was not statistically significant in either the MED group (49 vs. 
53% in Q1 and Q4, respectively; log-rank p =0.338) or CABG group (35 vs 39% in Q1 and Q4, 
respectively; log-rank p=0.103) (Figure 1). CV deaths accounted for a greater proportion of 
all deaths in the young (79% in the youngest quartile vs 62% in the oldest quartile). 
 
Effect of age on the impact of CABG 
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There was a trend towards a greater reduction in all-cause mortality with CABG compared 
to guideline-directed medical therapy in younger compared with older patients (HR in those 
age ≤54 years =0.66, 95%CI 0.49-0.89, HR in those age >67 years = 0.82, 95%CI 0.63-1.06, 
pinteraction=0.062). The efficacy of CABG in reducing CV mortality was consistent across all age 
groups (Figure 2 and Supplemental Material; HR in those age ≤54 years =0.61, 95%CI 0.43-
0.85, HR in those >67 years = 0.70, 95%CI 0.50-0.97, pinteraction =0.307). CABG resulted in a 
greater reduction in all-cause death and CV hospitalizations compared with medical therapy 
alone, and the effect was greater in the young (HR in those age ≤54 years =0.55, 95%CI 0.43-
0.71, HR in those age >67 years = 0.73, 95%CI 0.57-0.92, pinteraction=0.004). Non-CV deaths in 
the group randomized to CABG were not statistically different from the group randomized 
to medical therapy and did not vary by age (Table 5).  
 
The numbers of patients crossing from medical therapy to CABG and from CABG to medical 
therapy was low and there was no difference in either by age (ptrend=0.25 and 0.62, 
respectively). The “as-treated” analysis demonstrated similar findings with perhaps an even 
greater impact of age on the effects of CABG v medical therapy on 10 year outcomes (ie 
greater benefit in younger patients and less benefit in older patients across all end points) 
when compared with as the intention to treat analysis (Supplemental Material).  
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Discussion 
 
This analysis of the long-term follow-up of the STICH trial demonstrates that the benefit of 
CABG compared to guideline-directed medical therapy on all-cause mortality and the 
combination of all-cause mortality and CV hospitalizations is greater in younger compared 
with older patients. In contrast, the benefit of CABG on CV mortality is similarly seen across 
all age groups.   The discrepancy between the effect of CABG across ages as it relates to CV 
mortality and all-cause mortality likely results from the greater proportion of non-CV deaths 
in older patients, deaths that are less likely to be avoided by CABG.   
 
 An understanding of the efficacy of CABG in patients of different ages is needed to help 
inform clinical decision making.11   In the STICH trial, older patients had higher all-cause 
mortality compared with younger patients, whether they were randomized to medical 
therapy or CABG. This result is consistent with recent HF trials12, and previous surgical trials 
in patients without severe left ventricular dysfunction11. It is not surprising, as in STICH older 
patients had more co-morbidities and were more likely to die of non-cardiovascular causes 
than younger patients.  
 
In the present analyses, while CV mortality increased with age, it was not statistically 
significantly higher in the older compared with younger patients, suggesting that in patients 
such as those in STICH, with CAD, HF, and an ejection fraction ≤35%, the risk associated with 
their cardiovascular disease somewhat attenuates the risks associated with age, and the co-
morbidities that go along with age. The efficacy of CABG over medical therapy on CV 
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mortality persisted across all ages despite more co-morbidities and slightly higher early 
post-operative mortality in older patients. A further explanation for the finding may be the 
excellent medical therapy received by STICH patients, regardless of age. Medical therapies 
used in the treatment of HF are similarly effective across the spectrum of age. 12,13  Use of 
guideline recommended medical therapies was lower in the older patients but not different 
between the randomized groups in any age group, and is unlikely to have biased our 
findings. The use of implantable cardioverter defibrillators (ICD) was low at baseline (the 
population was recruited from 2002-2007 and the benefit of primary prevention ICDs 
reported in 2004/5). Greater use of ICDs might have reduced the risk of CV death in STICH. 
As the rate of ICD use was similarly low across the age range and in both treatment groups, 
we do not believe under-use of ICDs biased our results. However, the rate of sudden death 
in our cohort may have been higher than in contemporary real world cohorts and therefore 
the potential benefit of CABG may be lower. As STICH is the only contemporary CABG trial 
of patients with HF and significant LV dysfunction, there are no trials with which to compare 
these findings.   
 
Our finding that CABG had a consistent effect in all ages on the outcome that it is most likely 
to influence, CV death, is of clinical relevance.  Cardiologists and surgeons can recommend 
surgical revascularization for patients with CAD amenable to CABG and HF knowing that a 
reduction in CV death is seen across the spectrum of age of those included in the STICH trial. 
The lack of effect of CABG on all-cause mortality in older patients is a consequence of two 
findings. First, CV deaths accounted for a greater proportion of all deaths in the younger 
compared to older patients (79% of deaths in the youngest quartile, but 62% of deaths in 
the older). Secondly, it may be unreasonable to expect CABG to reduce non-CV deaths. Of 
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more concern in older patients was that CABG may in fact increase non-CV deaths through a 
greater burden of co-morbidities which in turn lead to a greater risk of post-operative 
complications and non-CV deaths.  In this surgical trial, it was important to analyze all 
causes of death to ensure no harm.  This is in contrast to trials of medical therapies where 
CV death is often the primary mortality endpoint, as there is less of a concern about 
increasing non-CV deaths.  Although the numbers were small, we observed no difference in 
the numbers of non-CV deaths in the two treatment arms in the oldest quartile. Thus our 
finding that CABG did not reduce all-cause mortality in the older group was not entirely 
unexpected. It was reassuring that CABG on top of guideline-directed medical therapy did 
not result in an iatrogenic increase in the risk of all cause death. 
 
This study has a number of limitations. Due to the relatively small numbers of women we 
were unable to examine potential interactions of sex with age and assigned strategy.14 This 
was a post-hoc, subgroup analysis, and was therefore not included in the power calculations 
for the original trial. Therefore, our findings should be considered exploratory rather than 
confirmatory. The patients and outcomes in the STICH trial may not be entirely 
representative of real world populations due to the selection bias that occurs when any trial 
is conducted. The outcomes may also have been better as sites were selected on the basis 
of their surgical expertise (they had to demonstrate a 30-day mortality of ≤5% for patients 
with a similar profile to those meeting the STICH inclusion criteria). There were few patients 
in the truly older age groups (75 (6%) were aged >75 of age and 15 (1%) over>=80 years of 
age). In older patients the true rate of complications and potential for long term benefit 
may be different.   
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In conclusion, the consistent benefit of CABG on CV mortality regardless of age supports the 
recommendation of surgical revascularization to reduce cardiovascular death in patients 
with severe LV dysfunction across all ages studied. As CV deaths accounted for more deaths 
in the younger age group, they tend to gain a greater reduction in all-cause mortality.  
Careful assessment of competing mortality risk is important prior to pursuing 
revascularization in older patients. 
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Figure Legends 
 
Figure1. Kaplan-Meier rates of all cause death, cardiovascular death and all cause death or 
CV hospitalization as a function of time from randomization by quartiles of age in patients 
randomized to CABG and patients randomized to medical therapy. MED= medical therapy, 
CABG=coronary artery bypass grafting. 
Figure  2. Hazard ratio (solid line) and 95% confidence interval (grey area) for the effect of 
CABG vs medical therapy across the range of age. 
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Table 1 Baseline Characteristics by Age  
 
Variable 
Baseline Age Quartiles 
P-value 
for trend 
Q1  
(Age≤54 years) 
(n=330) 
Q2  
(54<Age≤60 
years) 
(n=295) 
Q3  
(60<Age≤67 
years) 
(n=279) 
Q4  
(Age>67 years) 
(n=308) 
 
Age (year) 50(47,53) 57(56,58) 64(62, 65) 72(69,75)  
 
Women  35(11%) 26(9%) 37(13%) 50(16%) 0.011 
 
White race 187(57%) 189(64%) 200(72%) 251(82%) <0.001 
 
BMI (kg/m2) 27(24,31) 27(24,30) 27(24,30) 26(24,29) 0.180 
Medical History:      
    Diabetes  103(31%) 121(41%) 124(44%) 130(42%) 0.003 
    Hypertension   178(54%) 177(60%) 159(57%) 214(70%) <0.001 
    PVD  36(11%) 40(14%) 42(15%) 66(21%) <0.001 
    Renal insufficiency 10(3%)  16(5%) 25(9%) 43(14%) <0.001 
    Stroke 23(7%) 14(5%) 21(8%) 34(11%) 0.028 
    Atrial flutter/ 
fibrillation   19(6%) 25(9%) 42(15%) 67(22%) <0.001 
    Previous MI  250(76%) 229(78%) 208(75%) 247(80%) 0.320 
    Hyperlipidemia 190(58%) 174(59%) 181(65%) 185(60%) 0.286 
    Depression 24(7%) 17(6%) 15(5%) 20(7%) 0.646 
    Current smoker 104(32%) 64(22%) 50(18%) 34(11%) <0.001 
    Previous PCI   45(14%) 38(13%) 38(14%) 35(11%) 0.465 
    Previous CABG 8(2%) 10(3%) 11(4%) 7(2%) 0.974 
CCS angina class:       
    No angina 106(32%) 97(33%) 91(33%) 148(48%) <0.001 
    I 42(13%) 44(15%) 52(19%) 49(16%) 0.145 
    II 169(51%) 141(48%) 119(43%) 96(31%) <0.001 
    III 10(3%) 12(4%) 15(5%) 11(4%) 0.551 
    IV 3(1%) 1(<1%) 2(1%) 4(1%) 0.583 
NYHA class:      
    I  35(11%) 50(17%) 22(8%) 32(10%) 0.276 
    II 185(56%) 134(45%) 157(56%) 150(49%) 0.318 
    III 100(30%) 106(36%) 93 7(33%) 113(37%) 0.152 
    IV 10(3%) 5(2%) 7(3%) 13(4%) 0.315 
 
Median systolic BP 
(mmHg) 120(110,130) 120(110,130) 120(110,130) 122(110,136) <0.001 
 
Median heart  rate 
(bpm) 76(68,84) 75(68,82) 74(66,82) 
 
71(63,80) <0.001 
 
Median 6 minute 
walk distance (meter) 352(259,434) 360(273,415) 340(270,400) 321(250,385) <0.001 
 
Lab measures:      
   Hemoglobin (g/dL) 14.3(13.2,15.4) 13.9(12.7,14.9) 13.7(12.6,14.8) 13.6(12.3,14.6) <0.001 
   Creatinine (mg/dL) 1.02(0.90,1.18) 1.10(0.97,1.23) 1.10(0.94,1.30) 1.17(1.00,1.40) <0.001 
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   Sodium (mEq/L) 139(137,142) 140 (137, 142) 140(138,142) 140(137,142) 0.143 
   BUN (mg/dL) 22(15,37) 21 (16, 34) 21(16,36) 24(18,39) 0.031 
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Table 2 Baseline Medical and Device Therapies by Age 
 
 
Variable N(%) 
 
Baseline Age Quartiles 
P-value 
for 
Trend 
Q1  
(Age≤54 
years) 
(n=330) 
Q2  
(54<Age≤60 
years) 
(n=295) 
Q3  
(60<Age≤67 
years) 
(n=279) 
Q4  
(Age>67 
years) 
(n=308) 
 
Beta-blocker 282(86%) 247(84%) 250(90%) 257(83%) 0.946 
 
ACE inhibitor 267(81%) 248(84%) 233(84%) 248(81%) 0.879 
 
ARB 27(8%) 23(8%) 23(8%) 42(14%) 0.023 
 
ACE or ARB 288(87%) 263(89%) 252(90%) 282(92%) 0.068 
 
Statin 271(82%) 242(82%) 230(82%) 240(78%) 0.216 
 
Digoxin 68(21%) 62(21%) 55(20%) 60(20%) 0.651 
 
Aspirin 273(83%)             250(85%)   232(83%)        247(80%) 0.348 
 
Warfarin 25(8%)               23(8%)     35(13%)        44(14%) 0.001 
 
Clopidogrel 57(17%)                      57(19%)   47(17%) 47(15%) 0.387 
 
Diuretic      
   Loop/thiazide 200(61%)                 190(64%)     184(66%) 217(71%) 0.008 
   Potassium-sparing 161(49%)           137(46%)     136(49%)        122(40%) 0.042 
   Loop/thiazide or  
   potassium sparing 233(71%)        222(75%)       216(77%)        241(78%)   0.020 
 
Nitrate 166(50%)           154(52%)     162(58%)        164(53%) 0.232 
 
Insulin 42(13%)            54(18%)     49(18%)         52(17%) 0.191 
 
Oral antihyperglycemic 
agent 62(19%)  70(24%)       84(30%)        70(23%) 0.089 
 
Antidepressant 16(5%)            17(6%)        17(6%)          15(5%) 0.938 
Cardiac 
resynchronization 
therapy 3(1%) 0(0%) 1(<1%) 3(1%) 0.871 
Pacemaker 3(1%) 3(1%) 4(1%) 8(3%) 0.073 
ICD 11(3%) 6(2%) 8(3%) 4(1%) 0.161 
ACE – angiotensin converting enzyme inhibitor, ARB – angiotensin receptor blocker, ICD -  implantable 
cardioverter defibrillator 
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Table 3 Baseline Left Ventricular Structure and Function and Coronary Anatomy by Age 
 
 
Variable 
 
Baseline Age Quartiles 
P-value 
for 
Trend 
Q1  
(Age≤54 years) 
(n=330) 
Q2  
(54<Age≤60 
years) 
(n=295) 
Q3  
(60<Age≤67 
years) 
(n=279) 
Q4  
(Age>67 years) 
(n=308) 
 
Structure and function:      
 
   LVEF (%) 28(22,33) 28(23,35) 26(21,33) 28(22,34) 0.496 
 
   ESVI 81(62,103) 81(61,98) 77(60,105) 77(61,98) 0.179 
 
   EDVI 117(92,144) 113(90,139) 109(87,141) 108(87,135) 0.012 
 
   E velocity (m/s) 0.70(0.30,0.90) 0.70(0.50,0.90) 0.70(0.50,0.90) 0.60(0.50,0.85) <0.001 
 
   A velocity (m/s) 0.60(0.40,0.80) 0.70(0.50,0.80) 0.73(0.60,0.90) 0.70(0.60,0.90) <0.001 
 
   E/A ratio 1.00(0.75,2.25) 1.00(0.71,1.78) 0.80(0.63,1.57) 0.75(0.57,1.33) <0.001 
 
   E/e’ ratio (septal) 14(11,20) 17(12,23) 15(12,24) 17(11,23) 0.183 
 
   E/e’ ratio (lateral) 11(8,15) 12(9,16) 13(9,17) 12(8,17) 0.192 
 
   Anterior akinesia or 
dyskinesia (%) 43(30,57) 43(20,50) 43(29,57) 40(14,57) 0.155 
 
   MR severity:      
      None or trace 123(37%) 110(37%) 106(38%) 96(31%) 0.145 
      Mild 149(45%) 130(44%) 128(46%) 147(48%) 0.456 
      Moderate 43(13%) 47(16%) 38(14%) 53(17%) 0.240 
     Severe 14(4%) 8(3%) 7(3%) 10(3%) 0.460 
 
Coronary anatomy:      
 
  No of vessels with 
stenosis ≥ 50%         
       1     46(14%) 24(8%) 24(9%) 18(6%) <0.001 
       2 101(31%) 94(32%) 87(31%) 84(27%) 0.362 
       3 183(56%) 177(60%) 168(60%) 205(67%) 0.006 
 
   Stenosis of proximal 
LAD ≥75% 242(73%) 200(68%) 185(66%) 199(65%) 0.020 
 
   Duke CAD severity 
index 52(39,65) 65(39,77) 65(39,77) 65(39,77) 0.030 
LVEF – left ventricular ejection fraction, ESVI – end systolic volume indexed, EDVI  - end diastolic volume 
indexed, E - early diastolic filling velocity, A – atrial contraction induced diastolic filling velocity wave, e′ - early 
24 
 
diastolic myocardial velocity, MR – mitral regurgitation, LAD – left anterior descending , CAD – coronary artery 
disease
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Table 4 Procedural Details and Perioperative Complications by Age  
 
Variable 
 
Baseline Age Quartiles 
P-value 
for 
Trend 
Q1  
(Age≤54 
years) 
(n=149) 
Q2  
(54<Age≤60 
years) 
(n=127) 
Q3  
(60<Age≤67 
years) 
(n=131) 
Q4  
(Age>67 
years) 
(n=148) 
 
Number of conduits:         
      1     26(17%)              10(8%)         15(12%)           18(12%) 0.284 
      2 49(33%)                     37(29%)       42(32%)     47(32%) 0.958 
      3 60(40%)               60(47%)       52(40%)           64(43%) 0.894 
      ≥4   14(9%)                20(16%)       22(17%)           19(13%) 0.362 
 
Number of arterial 
conduits:         
      0     11(7%)             9(7%)            12(9%)            18(12%) 0.123 
      1 123(83%)                   104(82%)       104(79%)    115(78%) 0.249 
      ≥2 15(10%)           14(11%)                 15(12%)     15(10%) 0.957 
 
Number of distal 
anastomoses:         
      0  2(1%)             2(2%)             2(2%)             1(1%) 0.631 
      1      23(15%)                    10(8%)        14(11%)      16(11%) 0.319 
      2 41(28%)           27(21%)                  30(23%)    30(20%) 0.185 
      3 57(38%)               55(43%)       50(39%)           59(40%) 0.982 
      4   22(15%)           23(18%)           22(17%)           31(21%) 0.211 
      ≥5 4(3%)                 10(8%)       12(9%)            11(7%) 0.090 
 
Off-pump surgery 40(27%)                     24(19%)       25(19%)     27(18%) 0.083 
Total minutes on 
cardiopulmonary bypass 83(63,110)        92(72,125)                       93(66,110)                        89(70,126)               0.425 
Cross—clamp time in 
minutes 50(33,67)         55(41,79)                         54(35,72)                        56(39,80)            0.203 
Intensive Care Unit length 
of stay in hours 52(43,87)         61(42,94)                        49(27,97)                       65(40,112)                0.337 
Perioperative 
complications      
Return to operating room  7(5%)                 9(7%)         7(5%)            12(8%) 0.326 
Mediastinitis 3(2%)        4(3%)             2(2%)             2(1%) 0.516 
Other infection 9(6%)                  10(8%)       8(6%)            19(13%) 0.061 
New onset Atrial 
Fibrillation 10(7%)                 20(16%)      22(17%)           38(26%) <0.001 
Worsening renal 
impairment 2(1%)                4(3%)         12(9%)            16(11%) <0.001 
Intra-aortic balloon pump 25(17%)           22(17%)           24(18%)           18(12%) 0.335 
Inotrope Use 45(30%)           44(35%)                  56(43%)    71(48%) <0.001 
Cardiac arrest requiring 
cardiopulmonary 
resuscitation 3(2%)                3(2%)         10(8%)             7(5%) 0.079 
Pulmonary edema 
requiring intubation 3(2%)                 3(2%)         4(3%)             4(3%) 0.640 
Mortality within 30 days 
after CABG 3(2%)             5(4%)            10(8%)             8(5%) 0.081 
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Table 5  All deaths, deaths due to cardiovascular, non-cardiovascular  and unknown causes 
and all cause mortality or CV hospitalizations by quartiles of age 
Cause of death 
 
Randomized 
Treatment 
 
Baseline Age Quartiles 
Total 
(n=1212) 
P 
Value*  
Q1  
(Age≤54 
years) 
(n=330) 
Q2  
(54<Age≤60 
years) 
(n=295) 
Q3  
(60<Age≤67 
years) 
(n=279) 
Q4  
(Age>67 
years) 
(n=308) 
All cause CABG 76/160 
( 47.5%) 
76/143  
(53.1%) 
96/144  
(66.7%) 
111/163  
(68.1%) 
359/610  
(58.9%) 
0.004 
 MED 102/170  
(60.0%) 
90/152  
(59.2%) 
92/135  
(68.1%) 
114/145  
(78.6%) 
398/602  
(66.1%) 
 
        
Cardiovascular  
CABG 
56/160 
(35.0%) 
61/143 
(42.7%) 
67/144 
(46.5%) 
63/163 
(38.7%) 
247/610 
(40.5%) 
0.002 
 
MED 
84/170 
(49.4%) 
72/152 
(47.4%) 
64/135 
(47.4%) 
77/145 
(53.1%) 
297/602 
(49.3%) 
 
        
Non-
cardiovascular  
 
CABG 
10/160 
(6.3%) 
8/143 
(5.6%) 
21/144 
(14.6%) 
32/163 
(19.6%) 
71/610 
(11.6%) 
0.714 
 
MED 
9/170 
(5.3%) 
9/152 
(5.9%) 
20/135 
(14.8%) 
33/145 
(22.8%) 
71/602 
(11.8%) 
 
        
Unknown 
 
 
CABG 
10/160 
(6.3%) 
7/143 
(4.9%) 
8/144 
(5.6%) 
16/163 
(9.8%) 
41/610 
(6.7%) 
0.205 
 
MED  
9/170 
(5.3%) 
9/152 
(5.9%) 
8/135 
(5.9%) 
4/145 
(2.8%) 
30/602 
(5.0%) 
 
        
All cause death 
or CV 
hospitalization 
 
CABG 111/160  
(69.4%) 
101/143  
(70.6%) 
119/144  
(82.6%) 
136/163  
(83.4%) 
467/610  
(76.6%) 
 
<0.001 
  
MED  
147/170  
(86.5%) 
122/152  
(80.3%) 
122/135  
(90.4%) 
133/145  
(91.7%) 
524/602  
(87.0%) 
 
*P values are from the Cochran-Mantel-Haenszel test which do not account for time to event
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Figure 1. 
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Figure 2.  
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL MATERIAL 
  
Table S1: Number and percentage of patients by age category 
 
Distribution of age  
Age<=65 820 (68%) 
65<Age<=70 191(16%) 
70<Age<=75 126 (10%) 
75<Age<=80 60 (5%) 
Age>80 15 (1%) 
 
Table S2 Baseline Characteristics by Age  
 
Variable 
Baseline Age Quartiles 
P-value 
for 
trend1 
Q1  
(Aged54 
years) 
(n=330) 
Q2  
(54<Aged60 
years) 
(n=295) 
Q3  
(60<Aged67 
years) 
(n=279) 
Q4  
(Age>67 
years) 
(n=308) 
 
Age (year) 50(47, 53) 57(56, 58) 64(62, 65) 72 (69, 75)  
 
Female  35 (11%) 26 (9%) 37 (13%) 50 (16%) 0.011 
 
White race 187 (57%) 189 (64%) 200 (72%) 251 (82%) <0.001 
 
BMI (kg/m2) 27 (24, 31) 27 (24, 30) 27 (24, 30) 26 (24, 29) 0.178 
Medical History:      
    Diabetes  103 (31%) 121 (41%) 124 (44%) 130 (42%) 0.003 
    Hypertension   178 (54%) 177 (60%) 159 (57%) 214 (70%) <0.001 
    PVD  36 (11%) 40 (14%) 42 (15%) 66 (21%) <0.001 
    Renal insufficiency 10 (3%)  16 (5%) 25 (9%) 43 (14%) <0.001 
    Stroke 23 (7%) 14 (5%) 21 (8%) 34 (11%) 0.028 
    Atrial flutter/ 
fibrillation   19 (6%) 25 (9%) 42 (15%) 67 (22%) <0.001 
    Previous MI  250 (76%) 229 (78%) 208 (75%) 247 (80%) 0.320 
    Hyperlipidemia 190 (58%) 174 (59%) 181 (65%) 185 (60%) 0.286 
    Depression 24 (7%) 17 (6%) 15 (5%) 20 (7%) 0.646 
    Current smoker 104 (32%) 64 (22%) 50 (18%) 34 (11%) <0.001 
    Previous PCI   45 (14%) 38 (13%) 38 (14%) 35 (11%) 0.465 
    Previous CABG 8 (2%) 10 (3%) 11 (4%) 7 (2%) 0.974 
CCS angina class:       
    No angina 106 (32%) 97 (33%) 91 (33%) 148 (48%) <0.001 
    I 42 (13%) 44 (15%) 52 (19%) 49 (16%) 0.145 
    II 169 (51%) 141 (48%) 119 (43%) 96 (31%) <0.001 
    III 10 (3%) 12 (4%) 15 (5%) 11 (4%) 0.551 
    IV 3 (1%) 1 (<1%) 2 (1%) 4 (1%) 0.583 
NYHA class:      
    I  35 (11%) 50 (17%) 22 (8%) 32 (10%) 0.276 
    II 185 (56%) 134 (45%) 157 (56%) 150 (49%) 0.318 
    III 100 (30%) 106 (36%) 93 (33%) 113 (37%) 0.152 
    IV 10 (3%) 5 (2%) 7 (3%) 13 (4%) 0.315 
 
Median systolic BP 
(mmHg) 
120 (110, 
130) 120 (110, 130) 120 (110, 130) 
122 (110, 
136) <0.001 
 
Median heart  rate 
(bpm) 76 (68, 84) 75 (68, 82) 74 (66, 82) 
 
71 (63, 80) <0.001 
 
Median 6 minute walk 
distance (meter) 
352 (259, 
434) 360 (273, 415) 340 (270, 400) 
321 (250, 
385) <0.001 
 
Lab measures:      
   Hemoglobin (g/dL) 14.3 (13.2, 
15.4) 
13.9 (12.7, 
14.9) 
13.7 (12.6, 
14.8) 
13.6 (12.3, 
14.6) <0.001 
   Creatinine (mg/dL) 1.02 (0.90, 
1.18) 
1.10 (0.97, 
1.23) 
1.10 (0.94, 
1.30) 
1.17 (1.00, 
1.40) <0.001 
   Sodium (mEq/L) 139 (137, 140 (137, 142) 140 (138, 142) 140 (137, 0.086 
142) 142) 
   BUN (mg/dL) 22 (15, 37) 21 (16, 34) 21 (16, 36) 24 (18, 39) 0.016 
1. P-values for categorical variables are based on Cochran-Armitage Trend test.  Spearman correlation 
test is performed to get the p-values for continuous variables and the continuous age variable.  
 
 
 
 
Table S3 Baseline Left Ventricular Structure and Function and Coronary Anatomy by 
Age 
 
 
Variable 
 
Baseline Age Quartiles 
P-value 
for 
Trend1 
Q1  
(Aged54 
years) 
(n=330) 
Q2  
(54<Aged60 
years) 
(n=295) 
Q3  
(60<Aged67 
years) 
(n=279) 
Q4  
(Age>67 
years) 
(n=308) 
 
Structure and function:      
 
   LVEF (%) 28 (22, 33) 28 (23, 35) 26 (21, 33) 28 (22, 34) 0.518 
 
   ESVI 81 (62, 103) 81 (61, 98) 77 (60, 105) 77 (61, 98) 0.190 
 
   EDVI 117 (92, 144) 113 (90, 139) 109 (87, 141) 108 (87, 135) 0.020 
 
   E velocity (m/s) 
0.70 (0.30, 
0.90) 
0.70 (0.50, 
0.90) 
0.70 (0.50, 
0.90) 
0.60 (0.50, 
0.85) <0.001 
 
   A velocity (m/s) 
0.60 (0.40, 
0.80) 
0.70 (0.50, 
0.80) 
0.73 (0.60, 
0.90) 
0.70 (0.60, 
0.90) <0.001 
 
   E/A ratio 
1.00 (0.75, 
2.25) 
1.00 (0.71, 
1.78) 
0.80 (0.63, 
1.57) 
0.75 (0.57, 
1.33) <0.001 
 
   E/e’ ratio (septal) 14 (11, 20) 17 (12, 23) 15 (12, 24) 17 (11, 23) 0.129 
 
   E/e’ ratio (lateral) 11 (8, 15) 12 (9, 16) 13 (9, 17) 12 (8, 17) 0.222 
 
   Anterior akinesia or 
dyskinesia (%) 43 (30, 57) 43 (20, 50) 43 (29, 57) 40 (14, 57) 0.146 
 
   MR severity:      
      None or trace 123 (37%) 110 (37%) 106 (38%) 96 (31%) 0.145 
      Mild 149 (45%) 130 (44%) 128 (46%) 147 (48%) 0.456 
      Moderate 43 (13%) 47 (16%) 38 (14%) 53 (17%) 0.240 
     Severe 14 (4%) 8 (3%) 7 (3%) 10 (3%) 0.460 
 
Coronary anatomy:      
 
  No of vessels with 
stenosis e  50%         
       1     46 (14%) 24 (8%) 24 (9%) 18 (6%) <0.001 
       2 101 (31%) 94 (32%) 87 (31%) 84 (27%) 0.362 
       3 183 (56%) 177 (60%) 168 (60%) 205 (67%) 0.006 
 
   Stenosis of proximal 
LAD ≥75% 242 (73%) 200 (68%) 185 (66%) 199 (65%) 0.020 
 
   Duke CAD severity 
index 52 (39, 65) 65 (39, 77) 65 (39, 77) 65 (39, 77) 0.039 
1. P-values for categorical variables are based on Cochran-Armitage Trend test.  Spearman correlation 
test is performed to get the p-values for continuous variables and the continuous age variable.  
 
 
 
LVEF – left ventricular ejection fraction, ESVI – end systolic volume indexed, EDVI  - end diastolic volume 
indexed, E - early diastolic filling velocity, A – atrial contraction induced diastolic filling velocity wave, e2 - 
early diastolic myocardial velocity, MR – mitral regurgitation, LAD – left anterior descending , CAD – 
coronary artery disease 
Table S4 Procedural Details and Perioperative Complications by Age  
 
Variable 
 
Baseline Age Quartiles 
P-value 
for 
Trend1 
Q1  
(Aged54 
years) 
(n=149) 
Q2  
(54<Aged60 
years) 
(n=127) 
Q3  
(60<Aged67 
years) 
(n=131) 
Q4  
(Age>67 
years) 
(n=148) 
 
Number of conduits:         
      1     26 (17%)              10 (8%)         15 (12%)           18 (12%) 0.284 
      2 49 (33%)                     37 (29%)       42 (32%)     47 (32%) 0.958 
      3 60 (40%)               60 (47%)       52 (40%)           64 (43%) 0.894 
      e4   14 (9%)                20 (16%)       22 (17%)           19 (13%) 0.362 
 
Number of arterial 
conduits:         
      0     11 (7%)             9 (7%)            12 (9%)            18 (12%) 0.123 
      1 123 (83%)                   104 (82%)       104 (79%)    115 (78%) 0.249 
      e2 15 (10%)           14 (11%)                 15 (12%)     15 (10%) 0.957 
 
Number of distal 
anastomoses:         
      0  2 (1%)             2 (2%)             2 (2%)             1 (1%) 0.631 
      1      23 (15%)                    10 (8%)        14 (11%)      16 (11%) 0.319 
      2 41 (28%)           27 (21%)                  30 (23%)    30 (20%) 0.185 
      3 57 (38%)               55 (43%)       50 (39%)           59 (40%) 0.982 
      4   22 (15%)           23 (18%)           22 (17%)           31 (21%) 0.211 
      e5 4 (3%)                 10 (8%)       12 (9%)            11 (7%) 0.090 
 
Off-pump bypass 40 (27%)                     24 (19%)       25 (19%)     27 (18%) 0.083 
Total minutes on bypass 83 (63, 110)        92 (72, 125)                       93 (66, 110)                        89 (70, 126)               0.262 
Cross—clamp time in 
minutes 50 (33, 67)         55 (41, 79)                         54 (35, 72)                        56 (39, 80)            0.097 
Intensive Care Unit length 
of stay in hours 52 (43, 87)         61 (42, 94)                        49 (27, 97)                       65 (40, 112)                0.124 
Perioperative 
complications      
Return to operating room  7 (5%)                 9 (7%)         7 (5%)            12 (8%) 0.326 
Mediastinitis 3 (2%)        4 (3%)             2 (2%)             2 (1%) 0.516 
Other infection 9 (6%)                  10 (8%)       8 (6%)            19 (13%) 0.061 
New onset Atrial 
Fibrillation 10 (7%)                 20 (16%)      22 (17%)           38 (26%) <0.001 
Worsening renal 
impairment 2 (1%)                4 (3%)         12 (9%)            16 (11%) <0.001 
Intra-aortic balloon pump 25 (17%)           22 (17%)           24 (18%)           18 (12%) 0.335 
Inotropes for low cardiac 
output 45 (30%)           44 (35%)                  56 (43%)    71 (48%) <0.001 
Cardiac arrest requiring 
cardiopulmonary 
resuscitation 3 (2%)                3 (2%)         10 (8%)             7 (5%) 0.079 
Pulmonary edema requiring 
intubation 3 (2%)                 3 (2%)         4 (3%)             4 (3%) 0.640 
Mortality within 30 days 
after CABG 3 (2%)             5 (4%)            10 (8%)             8 (5%) 0.081 
1. P-values for categorical variables are based on Cochran-Armitage Trend test.  Spearman correlation 
test is performed to get the p-values for continuous variables and the continuous age variable.  
 
 
 
 
 
 
 
 
 
 
 
Table S5: Medical therapy at randomization and at 10 years in each quartile of age by randomized therapy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Q1  (Age≤54 years)  
N(%) 
 
Q2 (54<Age≤60 
years)  N(%) 
 
Q3 (60<Age≤67 years) 
 N(%) 
Q4 (Age>67 years)   
N(%) 
  Overall MED CABG P Overall MED CABG P Overall MED CABG P Overall MED CABG P 
Betablocker Randomization 282  
(85)  
148  
(87)          
134  
(84)          
0.39 247  
(84)       
   135  
(89)          
112  
(78)          
0.01 250  
(90)          
124  
(92)          
126  
(88)          
0.23 257  
(83)          
122  
(84)          
135  
(83)          
0.76 
 At 10 year 
follow up 
280  
(91)          
143  
(91)          
137  
(91)          
0.80 246  
(89)          
130  
(92)          
116  
(87)          
0.24 228  
(91)          
117  
(91)          
111  
(91)          
0.94 223  
(79)          
110  
(80)          
113  
(78)          
0.63 
                  
ACE inhibitor 
or ARB 
Randomization 288  
(87)          
149  
(88)          
139  
(87)          
0.83 263  
(89)          
132  
(87)          
131  
(92)          
0.19 252  
(90)          
121  
(90)          
131  
(91)  
0.70 282  
(92)          
129  
(89)          
153  
(94)          
0.12 
 At 10 year 
follow up 
269  
(87)          
142  
(90)          
127  
(85)          
0.17 233  
(85)          
119  
(84)          
114  
(86)          
0.66 226  
(90)          
118  
(91)          
108  
(89)          
0.44 211  
(75)          
104  
(76)          
107  
(74)          
0.68 
                  
Statin Randomization 271  
(82)          
147  
(86)          
124  
(78)          
0.03 242  
(82)          
126  
(83)          
116  
(81)          
0.69 230  
(82)          
118  
(87)          
112  
(78)          
0.03 240  
(78)          
109  
(75)          
131  
(80)          
0.27 
 At 10 year 
follow up 
264  
(86)          
135  
(85)          
129  
(86)          
0.89 230  
(84)          
118  
(83)          
112  
(84)          
0.80 225  
(90)          
115  
(89)          
110  
(90)          
0.79 230  
(82)          
110  
(80)          
120  
(83)          
0.59 
                  
Aspirin Randomization 273  
(83)          
145  
(85)          
128  
(80)          
0.20 250  
(85)          
129  
(85)          
121  
(85)          
0.95 232  
(83)          
116  
(86)         
 116  
(81)          
0.23 247  
(80)          
123  
(85)          
124  
(76)          
0.05 
 At 10 year 
follow up 
272  
(88)        
141  
(89)      
131  
(87)          
0.60 237  
(86)          
118  
(83)          
119  
(89)          
0.13 203  
(81)          
110  
(85)         
  93  
(76)          
0.07 203  
(72)           
97  
(71)          
106  
(73)          
0.67 
                  
Warfarin Randomization 25   
(8)            
17  
(10)            
8   
(5)           
0.09 23   
(8)            
17  
(11)           
 6   
(4)           
0.03 35   
(13)           
20  
(15)          
 15  
(10)          
0.27 44   
(14)          
 22  
(15)           
22  
(13)          
0.67 
 At 10 year 
follow up 
39   
(13)          
 18  
(11)           
21  
(14)          
0.49 47   
(17)           
26  
(18)          
 21  
(16)          
0.58 45   
(18)           
24  
(19)           
21  
(17)          
0.77 74   
(26)         
  36  
(26)          
 38  
(26)          
0.99 
                  
Potassium 
sparing 
diuretic 
Randomization 161  
(49)           
84  
(49)           
77  
(48)          
0.82 137  
(46)           
70  
(46)           
67  
(47)          
0.89 136  
(49)           
67  
(50)           
69  
(48)          
0.77 122  
(40)          
 55  
(38)           
67  
(41)          
0.57 
 At 10 year 
follow up 
173  
(56)           
86  
(54)           
87  
(58)          
0.53 147  
(53)           
75  
(53)           
72  
(54)          
0.83 150  
(60)           
80  
(62)          
 70  
(57)          
0.45 127  
(45)          
 59  
(43)           
68  
(47)          
0.52 
Table S6: Cross overs from each treatment arm by quartile of age.  
 
Randomized 
Treatment 
 
Baseline Age Quartiles 
Total 
(n=1212) 
P 
Value  
Q1  
(Aged54 
years) 
(n=330) 
Q2  
(54<Aged60 
years) 
(n=295) 
Q3  
(60<Aged67 
years) 
(n=279) 
Q4  
(Age>67 
years) 
(n=308) 
MED patients 
who crossed 
over to CABG 
24/170  
(14.1) 13/152  (8.6) 16/135  (11.9) 
13/145  
(9.0) 
66/602  
(11.0) 0.25 
CABG 
patients who 
crossed over 
to MED 
11/160  
(6.9) 16/143  (11.2) 13/144  (9.0) 
15/163  
(9.2) 55/610  (9.0) 0.62 
 
Table S7: Hazard ratios and 95% confidence intervals for CABG plus optimal medical therapy versus 
optimal medical therapy alone by quartile of age 
 
Q1  
(Aged54 years) 
(n=330) 
Q2  
(54<Aged60 
years) 
(n=295) 
Q3  
(60<Aged67 years) 
(n=279) 
Q4  
(Age>67 years) 
(n=308) 
 
All-cause death 0.66 (0.49, 0.89) 0.87 (0.64, 1.18) 
 
1.00 (0.75, 1.33) 0.82 (0.63, 1.06) 
 
Cardiovascular 
death 0.61 (0.43, 0.85) 0.88 (0.63, 1.24) 1.02 (0.73, 1.44) 0.70 (0.50, 0.97) 
 
Death or 
cardiovascular 
hospitalization 0.55 (0.43, 0.71) 0.81 (0.62, 1.05) 0.85 (0.66, 1.09) 0.73 (0.57, 0.92) 
Figure S1 Hazard ratio (solid line) and 95% confidence interval (grey area) for the 
effect of CABG vs medical therapy across the range of age- as treated analysis 
accounting for cross overs 
  
